Geduld E E buys $334,950 stake in Aclaris Therapeutics Inc (ACRS)

Aclaris Therapeutics Inc (ACRS) : Geduld E E scooped up 6,729 additional shares in Aclaris Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 17,500 shares of Aclaris Therapeutics Inc which is valued at $334,950.Aclaris Therapeutics Inc makes up approximately 0.46% of Geduld E E’s portfolio.

Other Hedge Funds, Including , Turner Investments sold out all of its stake in ACRS during the most recent quarter. The investment firm sold 87,004 shares of ACRS which is valued $1,646,986. Eam Investors added ACRS to its portfolio by purchasing 36,142 company shares during the most recent quarter which is valued at $684,168. Aclaris Therapeutics Inc makes up approx 0.10% of Eam Investors’s portfolio. Swiss National Bank added ACRS to its portfolio by purchasing 15,300 company shares during the most recent quarter which is valued at $288,864. Great West Life Assurance Co Can added ACRS to its portfolio by purchasing 1,200 company shares during the most recent quarter which is valued at $22,656. Monashee Investment Management added ACRS to its portfolio by purchasing 60,000 company shares during the most recent quarter which is valued at $1,132,800. Aclaris Therapeutics Inc makes up approx 1.73% of Monashee Investment Management’s portfolio.

Many Wall Street Analysts have commented on Aclaris Therapeutics Inc. Guggenheim Initiated Aclaris Therapeutics Inc on Jun 10, 2016 to “Buy”, Price Target of the shares are set at $35.

Aclaris Therapeutics Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis a non-cancerous skin tumor as well as for other cutaneous indications such as common warts. In addition the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company’s products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company’s A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company’s A-201 and A-301 products are in pre- clinical stage.

Leave a Reply

Aclaris Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aclaris Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.